Objective: There is evidence that gag contributes to protease inhibitor susceptibility in treatment-experienced patients. Moreover, protease inhibitor resistance-associated mutations can arise in gag in the absence of protease mutations in vitro. We wished to assess the contribution of full-length Gag to protease inhibitor susceptibility in viruses unexposed to protease inhibitors, in particular from the most common HIV-1 subtypes, namely subtype A and C.
Introduction
HIV-1 protease cleaves Gag and Gag-Pol polyproteins during virus maturation. Gag mutations involving cleavage sites, in particular p7/p1, p1/p6, have been associated with drug resistance or recovery of replicative capacity both in the absence [1] and presence [2] [3] [4] of protease drug resistance-associated mutations. Polymorphisms at these positions as well as the p24/p2 and p2/p7 cleavage site have also been documented in drug-naive patients [3, 5] . Furthermore, we and others have identified areas of the Gag protein from protease inhibitor-treated patients that are associated with both drug resistance and recovery of replicative capacity (outside cleavage site regions) [6] [7] [8] . Polymorphisms throughout gag may, therefore, be relevant to response to protease inhibitors in naive patients. Despite this body of data, phenotypic testing of clinical samples is still focused, primarily on the protease gene. Phenotypic resistance test vectors have generally incorporated patient-derived protease and the 5 0 end of gag (including p7/p1 and p1/p6 cleavage sites) into a gag-containing vector, typically derived from an HIV-1 subtype B molecular clone. There exists, therefore, the possibility of misclassifying drug susceptibility based on such an approach.
Non-B subtypes of HIV-1 account for the vast majority of infections worldwide. As the WHO public health rollout of HAART progresses, substantial numbers of patients will require second-line therapy with ritonavir-boosted protease inhibitors. As little in-vitro work has been undertaken on the basis of protease inhibitor susceptibility in full-length non-B viruses, we focused on protease inhibitor drug susceptibility in wild-type subtype A and C laboratory and clinical strains, not previously exposed to antiretrovirals, as these different subtypes provide a wide genetic diversity within protease and gag. We sought to explore the role of full-length gag as well as protease in determining protease inhibitor susceptibility in such wild-type viruses.
Materials and methods

Construction of resistance test vectors
A replication-defective, envelope-deleted subtype B clone p8.91NSX, expressing gag-pol, tat and rev was used as previously described [6] . This vector was further modified by silencing an existing EcoRI site at the end of integrase and creating a new EcoRI site just after the end of proteaseusing site-directed mutagenesis to allow cloning of gagprotease sequences. The two vectors had indistinguishable replication capacities and drug susceptibility profiles (data not shown). We obtained the following molecular clones from the National Institutes of Health (NIH) AIDS Research and Reference Reagent program: (subtype) p97ZA012.1 (C) [9] , p98CN006.29 (C) [9] , pMJ4 (C) [10] and p94CY017.41 (A) [11] . Additionally the gag-protease region was amplified from two treatment-naive patients, identified by phylogenetic analysis as having subtype A virus during routine genotypic testing at first HIV diagnosis. RNA was extracted from plasma virus (QIA amp viral RNA extraction kit; Qiagen, Venlo, The Netherlands) and reverse transcribed using Moloneymurine leukaemia virus-reverse transcriptase and random priming (Promega, Fitchburg, Wisconsin, USA). Gag-pol coding sequence was amplified from complementary DNA by nested PCR using outer primers 5 0 gagout (GTG TGG AAA ATC TCTAGC AG) and RTrev1 (CTG GRA TAA CYT CTG CTT) and an inner primer set as described [6] . Both PCR steps were carried out using Expand High Fidelity PCR kit (Boehringer Mannheim, Mannheim, Germany). The subtype A gag-protease sequences were cloned into the vector backbone, and representative clones (12.2 and 32G) chosen that had the same pol sequence as determined from plasma virus population sequencing. We utilized the naturally occurring ApaI restriction site towards the end of gag to generate chimeras between the test samples and the subtype B reference virus as used by commercial phenotypic systems.
Generation of virus stocks and drug susceptibility testing
293T cells were cotransfected with a gag-pol expression vector containing cloned gag-protease sequences, and plasmids encoding vesticular stomatitis virus G envelope and luciferase reporter genes, with protease inhibitor drug susceptibility testing carried out as previously described [6] . Results, derived from at least two independent experiments (each in duplicate) were analysed and fold changes in the concentration of drug required to inhibit 50% of viral replication (IC 50 ) determined using Graph Pad Prism 5 (GraphPad Software, Inc., La Jolla, California, USA). Susceptibility testing for reverse transcriptase inhibitors differed in that supernatantcontaining resistance test vectors was harvested 48 h after transfection, and used to infect fresh target 293T cells in the presence of serial dilutions of reverse transcriptase inhibitors in a 96-well plate format. Replicative capacity of these viruses was assessed by comparing the luciferase activity of recombinant virus to that of the wild-type subtype B control virus in the absence of drug. Equal amounts of input plasmid DNA were used and we have previously shown that percent infectivity correlates well with infectivity/ng p24 in this system [6] . The drugs used in this study [atazanavir (ATV), darunavir (DRV), lopinavir (LPV), saquinavir (SQV), zidovudine (ZDV) and nevirapine (NVP)] were obtained from the NIH AIDS Research and Reference Reagent Program.
Multiple sequence alignment was carried out using the program Muscle (www.drive5.com/muscle/) with manual alignment in Se-Al (tree.bio.ed.ac.uk).
Results
Discrepancy between gag-protease and protease alone vectors in protease inhibitor susceptibility We tested a panel of six viruses against the following protease inhibitors: ATV, DRV, LPV and SQV. Fold changes relative to subtype B are shown in Table 1 . For full-length gag-protease constructs we observed a range of protease inhibitor susceptibilities, with five out of six showing reduced susceptibility for at least one drug (using a generous biological cutoff of fold change >2, which is greater than the assay variability as determined by the standard deviations of repeated IC 50 values for the reference virus). Overall, there was a five-fold reduction in susceptibility to at least one drug in half the samples tested, with the greatest reductions seen for LPV, with more variable changes in susceptibility for ATVand SQV.
Importantly, however, when specific proteases from these viruses were tested in the context of the subtype B gag (Table 1) , as in most commercially available phenotypic drug resistance assays, a reversal of this reduction in susceptibility was generally observed. This use of the protease-alone vector resulted in overestimating the LPV susceptibility of CY017 by nearly 25 times, of ZA012 by nearly nine times and for 32G by a factor of seven, compared with the gag-protease vector ( Table 1) .
Gag alone confers reduced protease inhibitor susceptibility
In order to determine whether the determinants of reduced susceptibility in some of the viruses were located in gag, we examined the profile of our panel of gag sequences fused not with their cognate protease, but with the reference subtype B protease ( Fig. 1a ) and compared these with the full-length cognate gag-protease samples with regard to LPV susceptibility (Table 1) . We confirmed that gag alone determined reduced susceptibility to protease inhibitor. Notably, ZA012 gag with B protease showed 14-fold reduced susceptibility as compared with subtype B gag-protease. This experiment also demonstrates that the cognate protease restores susceptibility to protease inhibitor and, in the extreme case of MJ4, can completely reverse a partially resistant phenotype to a hypersusceptible one, in relation to subtype B.
There was variation in replicative capacity between constructs (Fig. 1b) . Interestingly, the cognate gagprotease combination had a lower replicative capacity than gag with a subtype B protease in both ZA012 and 32G. There was no direct correlation between protease inhibitor susceptibility and replicative capacity; for example, there was an 8.9-fold difference in LPV fold change for gag-protease versus protease alone in ZA012, but no difference in replicative capacity (Fig. 1b , compare white and grey bars). As a control for any potential impact of replication capacity on drug susceptibility, we performed phenotypic susceptibility testing for the panel of viral constructs against the reverse transcriptase Gag contributes to PI susceptibility in naive HIV-1 Gupta et al. 1653 Table 1 . Drug susceptibility profiles of a range of viruses comparing full-length gag-protease sequences with protease alone. inhibitors ZDV (Fig. 1c ) and NVP (data not shown). For both drugs, the fold changes relative to the subtype B reference were less than 1.5-fold across all constructs tested. We also confirmed that use of cognate gag-protease or cognate gag-protease-reverse transcriptase did not affect protease inhibitor susceptibility results (Fig. 1d ).
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Finally, we analysed gag and protease sequences from the seven viruses tested (Figures S1 and S2, http:// links.lww.com/QAD/A20 and http://links.lww.com/ QAD/A21). Comparison of gag cleavage sites (in boxes) shows that most are highly conserved, with the exception of p7/p2 ( Figure S1 , orange box, http://links.lww.com/ QAD/A20). Protease sequence analysis showed no major resistance mutations and typical non-B polymorphisms in subtypes A and C, some of which are classified as minor resistance mutations ( Figure S2 , http://links.lww.com/ QAD/A21).
Discussion
Overall, these data demonstrate that virus-specific protease confers variable susceptibility to protease inhibitors, and, more importantly, suggest that consideration of protease alone may overestimate protease inhibitor susceptibility in viruses not previously exposed to this class of drugs. This could lead to misclassification of susceptibility for some isolates, and potentially also limits assessment of the genotype-phenotype relationships in drug-experienced patients.
Given the expanding body of evidence showing that gag mutations are known to contribute to protease inhibitor resistance in treated patients, and in light of our data, we recommend that full gag sequences should be included in recombinant virus assays to determine protease inhibitor susceptibility in clinical isolates. We would also encourage a rapid expansion of full-length gag sequencing in patients failing protease inhibitor-based therapy to populate the relevant relational databases increasingly used to assess the clinical impact of HIV drug resistance. Gag genotypic determination to guide patient care can then be evaluated once specific Gag determinants of protease inhibitor susceptibility have been identified.
Lower clinical cutoffs of 5.2 and 10-fold have been proposed for ATVand LPV response, respectively [12, 13] . Although fold changes in our system may not be directly comparable, we were concerned to observe that some viruses approached and even exceeded these values. In the ACTG 5142 study, 23% of patients starting boosted LPV had a viral load of above 50 copies/ml after 2 years as compared with 11% for nonnucleoside reverse transcriptase inhibitor-based regimens (P ¼ 0.003) [14] . Patients with viral failure after boosted protease inhibitor in this and other studies [15, 16] infrequently have major protease resistance mutations, although there is a lack of data on evolution of Gag mutations. A better understanding of determinants in Gag-reducing susceptibility to protease inhibitor might explain these observations.
Finally, our findings may have important implications for the public health approach to ART. Increasing numbers of patients are moving to protease inhibitor-based second-line therapy following the rollout of HAART, and combined LPV-ritonavir is the most widely available protease inhibitor in resource-poor settings. Some of the subtype A and C constructs studied demonstrated particularly high fold changes for this agent, and as resistance testing is not routinely performed in these patients, further research is clearly warranted.
